Cognition Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

COGNITION THERAPEUTICS INC

Deficiency letter received on September 12, 2024; stock continues trading under CGTX.
Company has until March 11, 2025 to regain compliance under Nasdaq Rule 5450(a)(1).
If noncompliant, company may get second 180-day cure period upon transfer to Nasdaq Capital Market.
No assurance of regaining compliance; delisting could occur if not cured.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.